Looking for a Single Tech ETF? Do Not Overlook This Option.
There are plenty of good reasons that the Vanguard Information Technology ETF (VGT 1.69%) is one of the most popular exchange-traded funds (ETFs) on the market. For investors seeking an ETF focused on the technology sector, Vanguard’s fund provides broad exposure to America’s leading tech companies.If it isn’t already part of your portfolio, here’s what you should know before you invest in the Vanguard Information Technology ETF. » Read more about: Looking for a Single Tech ETF? Do Not Overlook This Option. »
Read MoreGoldman Sachs Dumps XRP and Solana ETFs, Slashes Ethereum Exposure by 70%
Key Takeaways
-
Goldman Sachs fully exited its XRP and Solana ETF positions and cut Ethereum exposure by roughly 70% in Q1 2026.
-
Harvard also reduced its Bitcoin ETF stake by 43% and completely exited Ethereum ETFs amid market volatility.
» Read more about: Goldman Sachs Dumps XRP and Solana ETFs, Slashes Ethereum Exposure by 70% »
Read MoreYou Could Lose Your Social Security Benefits to the Trump Administration’s Mistake
Quick Read
-
If the Social Security Administration makes a mistake and overpays you you could end up losing part of your benefits in the future if you’re asked to pay back the money and are unable to do so immediately.
-
The Social Security Administration can withhold up to 50% of retirement benefits to recover overpayments,
Stock market today: Dow, S&P 500, Nasdaq futures rise in countdown to Nvidia earnings
The Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Why This Beverage Giant Can’t Be Toppled
A famous book on business was titled Barbarians at the Gate, documenting the leveraged buyout of RJR Nabisco. If nothing else, it highlights how just the sniff of an opportunity to make money can drive money seekers to make wild decisions.
Some giant businesses have been on the receiving end of similar threats to their solvency as invaders attempt to take their share.
» Read more about: Why This Beverage Giant Can’t Be Toppled »